BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to the supportive care and treatment of cancer patients, announced the grant of a European patent protecting its product acyclovir Lauriad®. This patent is now validated in all European countries; this first patent...
BioAlliance Pharma SA (Euronext Paris - BIO) (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA (Food and Drug Administration) of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the...